Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial - Siena, S; Di Bartolomeo, M; Raghav, K (Lancet Oncol, 2021)
et al.